U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07383922) titled 'A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in CLDN18.2+ Pancreatic Cancer' on Jan. 26.
Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled phase 3 study designed to evaluate the efficacy and safety of FG-M108 injection combined with nab-paclitaxel and gemcitabine (Nab-P+GEM) versus placebo combined with Nab-P+GEM as first-line treatment in patients with CLDN18.2-positive, unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma.
Study Start Date: Feb. 28
Study Type: INTERVENTIONAL
Condition:
Pancreatic Cancer
Intervention:
DRUG: FG-M108
FG-M108 monoclonal antibody...